AQUILO CAPITAL MANAGEMENT LLC
Q4 2023 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001591986
· CRD 153022
· SEC-registered investment adviser
$160.5M Reported Value Total
AQUILO CAPITAL MANAGEMENT, LLC reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $257,631,514, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
3 funds
· $277.1M gross asset value
Hedge Fund: $189.4M · Other: $87.6M
Source: Form ADV filed 2024-03-26
Reported value
$160.5M
Quarter over quarter
+51.3%
Holdings
9
Top-10 concentration
100.0%
Key People
Form ADV owners & control persons
Marc Robert Schneidman
MANAGER
Adam Scott Bristol
MANAGING DIRECTOR - HEAD OF INVESTMENTS
Tony Michael Berta
CFO AND CCO
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2023 13F record
Q4 2023 13F filing summary
| Period of report | December 31, 2023 |
|---|---|
| Filed | February 14, 2024 |
| Form | 13F-HR |
| Reported value | $160.5M |
| Positions | 9 |
| Change in reported value | +45.4% |
| New positions | 2 |
| Exited positions | 5 |
| Position turnover | 50.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q1 2025 13F
Filed May 15, 2025
|
12 | $55.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
13 | $66.3M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
13 | $131.9M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $103.7M |
|
Q1 2024 13F
Filed May 15, 2024
|
10 | $133.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
9 | $160.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
12 | $110.4M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
12 | $180.5M |
|
Q1 2023 13F
Filed May 15, 2023
|
11 | $241.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
12 | $266.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
14 | $277.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
12 | $293.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
12 | $680.4M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
13 | $881.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
13 | $550.6M |
|
Q2 2021 13F
Filed Aug 16, 2021
|
15 | $384.9M |
|
Q1 2021 13F
Filed May 17, 2021
|
15 | $553.4M |
|
Q4 2020 13F
Filed Feb 16, 2021
|
15 | $481.2M |
|
Q3 2020 13F
Filed Nov 16, 2020
|
15 | $944.6M |
|
Q2 2020 13F
Filed Aug 14, 2020
|
13 | $495.9M |
6 earlier quarters on file — choose one from the quarter menu above.
Top 10 holdings · Q4 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ARWR ARROWHEAD PHARMACEUTICALS IN | $27.8M | 17.33% |
| 2 | BPMC BLUEPRINT MEDICINES CORP | $23.5M | 14.65% |
| 3 | KYMR KYMERA THERAPEUTICS INC | $22.4M | 13.98% |
| 4 | ARVN ARVINAS INC | $20.1M | 12.55% |
| 5 | SLN SILENCE THERAPEUTICS PLC | $18.1M | 11.29% |
| 6 | XBI P S&P BIOTECH ETF TR | $17.9M | 11.13% |
| 7 | RGNX REGENXBIO INC | $14.4M | 8.98% |
| 8 | MRUS MERUS N V | $9.8M | 6.09% |
| 9 | RPTX REPARE THERAPEUTICS INC | $4.6M | 2.88% |
| 10 | STRO SUTRO BIOPHARMA INC | $1.8M | 1.12% |
Values as reported on the Q4 2023 Form 13F. Every position is in the holdings table below.